Infecções graves ou oportunistas em pacientes com doença inflamatória intestinal: incidência e fatores de risco
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
The introduction of immunosuppressive agents, including biologics and Janus
kinase (JAK) inhibitors, has revolutionized the treatment of inflammatory bowel
disease (IBD), but raised concerns about the risk of severe and opportunistic
infections (OIs). This study aimed to evaluate the incidence and risk factors for
severe infections and OIs in patients with IBD undergoing immunosuppressive
therapy, compared to non-immunosuppressed patients. We conducted an
ambispective cohort study involving 498 adult patients with IBD followed at the IBD
Center of the University Hospital of the Federal University of Juiz de Fora, Brazil,
between March 2014 and April 2024. Retrospective data were collected from 2014
to 2021, and prospective data collection was carried out from 2021 onward. The
incidence rate (IR) was calculated as the number of events per 1,000 patient-years
(PY), and risks were assessed using Cox proportional hazard models adjusted for
age and sex. Over a total of 3,279.6 PY of follow-up, severe infections were identified
in 7% of patients (IR: 10.7/1,000 PY) and OIs in 12% (IR: 18.3/1,000 PY). The most
frequent OIs were herpes zoster (5.6%; IR: 8.5/1,000 PY) and tuberculosis (3.4%;
IR: 5.18/1,000 PY). The risk of OIs was significantly higher among patients receiving
combination therapy with anti-TNF and azathioprine (adjusted hazard ratio [aHR]:
6.86; 95% confidence interval [CI]: 1.97–23.92), followed by thiopurine monotherapy
(aHR: 5.02; 95% CI: 1.45–17.33) and anti-TNF monotherapy (aHR: 4.70; 95% CI:
1.39–15.96), compared to non-immunosuppressed patients. These findings
reinforce that anti-TNF and/or thiopurine therapy is associated with a higher risk of
OIs, particularly herpes zoster and tuberculosis. Therefore, therapeutic decisions in
IBD should carefully balance efficacy and long-term safety.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

